167 related articles for article (PubMed ID: 21693189)
21. Frosta: a new technology for making fast-melting tablets.
Jeong SH; Fu Y; Park K
Expert Opin Drug Deliv; 2005 Nov; 2(6):1107-16. PubMed ID: 16296813
[TBL] [Abstract][Full Text] [Related]
22. A dual strategy to improve psychotic patients' compliance using sustained release quetiapine oral disintegrating tablets.
Refaat A; Sokar M; Ismail F; Boraei N
Acta Pharm; 2016 Dec; 66(4):515-532. PubMed ID: 27749256
[TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo evaluation of nimesulide lyophilized orally disintegrating tablets.
Shoukri RA; Ahmed IS; Shamma RN
Eur J Pharm Biopharm; 2009 Sep; 73(1):162-71. PubMed ID: 19406232
[TBL] [Abstract][Full Text] [Related]
24. Factorial analysis of the influence of dissolution medium on drug release from carrageenan-diltiazem complexes.
Bonferoni MC; Rossi S; Ferrari F; Stavik E; Pena-Romero A; Caramella C
AAPS PharmSciTech; 2000 Jun; 1(2):E15. PubMed ID: 14727848
[TBL] [Abstract][Full Text] [Related]
25. Effect of core size and excipients on the lag time and drug release from a pulsatile drug delivery system.
Efentakis M; Iliopoyloy A; Siamidi A
Drug Dev Ind Pharm; 2011 Jan; 37(1):113-20. PubMed ID: 20615155
[TBL] [Abstract][Full Text] [Related]
26. Effects of disintegration-promoting agent, lubricants and moisture treatment on optimized fast disintegrating tablets.
Late SG; Yu YY; Banga AK
Int J Pharm; 2009 Jan; 365(1-2):4-11. PubMed ID: 18778759
[TBL] [Abstract][Full Text] [Related]
27. Effect of starch 1500 as a binder and disintegrant in lamivudine tablets prepared by high shear wet granulation.
Rahman BM; Ibne-Wahed MI; Khondkar P; Ahmed M; Islam R; Barman RK; Islam MA
Pak J Pharm Sci; 2008 Oct; 21(4):455-9. PubMed ID: 18930870
[TBL] [Abstract][Full Text] [Related]
28. Development of a multiple-unit tablet containing enteric-coated pellets.
Dreu R; Ilić I; Srčič S
Pharm Dev Technol; 2011 Apr; 16(2):118-26. PubMed ID: 20088675
[TBL] [Abstract][Full Text] [Related]
29. A scintigraphic investigation of the disintegration behaviour of capsules in fasting subjects: a comparison of hypromellose capsules containing carrageenan as a gelling agent and standard gelatin capsules.
Tuleu C; Khela MK; Evans DF; Jones BE; Nagata S; Basit AW
Eur J Pharm Sci; 2007 Mar; 30(3-4):251-5. PubMed ID: 17188473
[TBL] [Abstract][Full Text] [Related]
30. Risperidone solid dispersion for orally disintegrating tablet: its formulation design and non-destructive methods of evaluation.
Rahman Z; Zidan AS; Khan MA
Int J Pharm; 2010 Nov; 400(1-2):49-58. PubMed ID: 20801200
[TBL] [Abstract][Full Text] [Related]
31. Material and tablet properties of pregelatinized (thermally modified) Dioscorea starches.
Odeku OA; Schmid W; Picker-Freyer KM
Eur J Pharm Biopharm; 2008 Sep; 70(1):357-71. PubMed ID: 18562187
[TBL] [Abstract][Full Text] [Related]
32. Formulation and evaluation of a pulsatile drug delivery system using time- and pH-dependant polymers.
Kadam VD; Gattani SG
Pharm Dev Technol; 2010; 15(1):57-63. PubMed ID: 19552544
[TBL] [Abstract][Full Text] [Related]
33. The use of the SeDeM Diagram expert system to determine the suitability of diluents-disintegrants for direct compression and their use in formulation of ODT.
Aguilar-Díaz JE; García-Montoya E; Pérez-Lozano P; Suñe-Negre JM; Miñarro M; Ticó JR
Eur J Pharm Biopharm; 2009 Nov; 73(3):414-23. PubMed ID: 19602435
[TBL] [Abstract][Full Text] [Related]
34. Varying efficacy of superdisintegrants in orally disintegrating tablets among different manufacturers.
Mittapalli RK; Qhattal HS; Lockman PR; Yamsani MR
Pharmazie; 2010 Nov; 65(11):805-10. PubMed ID: 21155386
[TBL] [Abstract][Full Text] [Related]
35. Effect of processing methods on xylitol-starch base co-processed adjuvant for orally disintegrating tablet application.
Bin LK; Helaluddin ABM; Islam Sarker MZ; Mandal UK; Gaurav A
Pak J Pharm Sci; 2020 Mar; 33(2):551-559. PubMed ID: 32276897
[TBL] [Abstract][Full Text] [Related]
36. Compressed orally disintegrating tablets: excipients evolution and formulation strategies.
Al-khattawi A; Mohammed AR
Expert Opin Drug Deliv; 2013 May; 10(5):651-63. PubMed ID: 23387409
[TBL] [Abstract][Full Text] [Related]
37. The preparation of orally disintegrating tablets using a hydrophilic waxy binder.
Abdelbary G; Prinderre P; Eouani C; Joachim J; Reynier JP; Piccerelle P
Int J Pharm; 2004 Jul; 278(2):423-33. PubMed ID: 15196646
[TBL] [Abstract][Full Text] [Related]
38. Assessment of Albizia zygia gum as a binding agent in tablet formulations.
Odeku OA
Acta Pharm; 2005 Sep; 55(3):263-76. PubMed ID: 16375837
[TBL] [Abstract][Full Text] [Related]
39. Formulation and evaluation of Cetirizine dihydrochloride orodispersible tablet.
Subramanian S; Sankar V; Manakadan AA; Ismail S; Andhuvan G
Pak J Pharm Sci; 2010 Apr; 23(2):232-5. PubMed ID: 20363705
[TBL] [Abstract][Full Text] [Related]
40. Development and Optimization by Quality by Design Strategies of Frovatriptan Orally Disintegrating Tablets for Migraine Management.
Mennini N; Orlandini S; Furlanetto S; Pasquini B; Mura P
Curr Drug Deliv; 2018; 15(3):436-445. PubMed ID: 28595529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
